Literature DB >> 15568146

[Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].

A Goette1, U Lendeckel, H U Klein.   

Abstract

Atrial fibrillation (AF) is the most common clinical arrhythmia and one of the most important factors for embolic stroke. In recent years, a tremendous amount has been learned about the pathophysiology and molecular biology of AF. Thus, pharmacologic interference with specific signal transduction pathways appears promising as a novel antiarrhythmic approach to maintain sinus rhythm and to prevent atrial clot formation. This review highlights the underlying molecular biology of atrial fibrillation, which may also be relevant for AF therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15568146     DOI: 10.1007/s00392-004-0147-4

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  98 in total

1.  Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation.

Authors:  A Goette; P Hoffmanns; W Enayati; U Meltendorf; J C Geller; H U Klein
Journal:  Am J Cardiol       Date:  2001-10-15       Impact factor: 2.778

2.  Expression and activity of ectopeptidases in fibrillating human atria.

Authors:  U Lendeckel; M Arndt; S Wrenger; K Nepple; C Huth; S Ansorge; H U Klein; A Goette
Journal:  J Mol Cell Cardiol       Date:  2001-06       Impact factor: 5.000

3.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

4.  Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.

Authors:  S Shintani; T Murohara; H Ikeda; T Ueno; T Honma; A Katoh; K Sasaki; T Shimada; Y Oike; T Imaizumi
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

5.  Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies.

Authors:  Allen P Burke; Russell P Tracy; Frank Kolodgie; Gray T Malcom; Arthur Zieske; Robert Kutys; Joseph Pestaner; John Smialek; Renu Virmani
Journal:  Circulation       Date:  2002-04-30       Impact factor: 29.690

6.  Increased expression of P-selectin in patients with chronic atrial fibrillation.

Authors:  A Goette; A Ittenson; P Hoffmanns; S Reek; W Hartung; H Klein; S Ansorge; J C Geller
Journal:  Pacing Clin Electrophysiol       Date:  2000-11       Impact factor: 1.976

7.  Chimerism of the transplanted heart.

Authors:  Federico Quaini; Konrad Urbanek; Antonio P Beltrami; Nicoletta Finato; Carlo A Beltrami; Bernardo Nadal-Ginard; Jan Kajstura; Annarosa Leri; Piero Anversa
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

8.  Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study.

Authors:  A J Sanfilippo; V M Abascal; M Sheehan; L B Oertel; P Harrigan; R A Hughes; A E Weyman
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

Review 9.  Nonchannel drug targets in atrial fibrillation.

Authors:  Andreas Goette; Uwe Lendeckel
Journal:  Pharmacol Ther       Date:  2004-04       Impact factor: 12.310

Review 10.  Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

Authors:  H Matsubara
Journal:  Circ Res       Date:  1998 Dec 14-28       Impact factor: 17.367

View more
  2 in total

1.  Atrial fibrillation - patients at high risk for cerebral embolism.

Authors:  P Bernhardt; H Schmidt; T Sommer; B Lüderitz; H Omran
Journal:  Clin Res Cardiol       Date:  2006-01-12       Impact factor: 5.460

2.  Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design.

Authors:  Andreas Goette; Günter Breithardt; Thomas Fetsch; Peter Hanrath; Helmut U Klein; Walter Lehmacher; Gerhard Steinbeck; Thomas Meinertz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.